Steven Cohen Achilles Therapeutics PLC Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.79 - $2.39 $548,090 - $1.66 Million	-693,786 Reduced 32.92%	1,413,809 $1.27 Million
Q3 2022 Nov 14, 2022	BUY	$2.26 - $3.38 $747,723 - $1.12 Million	330,851 Added 18.62%	2,107,595 $4.76 Million
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $542,418 - $841,301	276,744 Added 18.45%	1,776,744 $4.48 Million
Q1 2022 May 16, 2022	BUY	$2.8 - $5.23 $1.4 Million - $2.62 Million	500,000 Added 50.0%	1,500,000 $4.41 Million
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $2.11 Million - $4.43 Million	500,000 Added 100.0%	1,000,000 $5.01 Million
Q3 2021 Nov 15, 2021	BUY	$5.81 - $9.93 $2.91 Million - $4.97 Million	500,000 New	500,000 $3.9 Million

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $42M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.